Cervical screening and risk of adenosquamous and rare histological types of invasive cervical carcinoma: population based nested case-control study

Abstract Objectives To examine the association of cervical cytology screening with the risk of adenosquamous cell carcinoma (ASC) and rare histological types of invasive cervical carcinoma (RICC), using comprehensive registry data, and to assess tumour human papillomavirus status of ASC and RICC. Design Nationwide, population based, nested case-control study. Setting Sweden. Participants All cases of invasive cervical carcinoma in Sweden during 2002-11 (4254 confirmed cases after clinical and histopathological review). 338 cases were neither squamous cell carcinoma nor adenocarcinoma, including 164 cases of ASC and 174 cases of RICC (glassy cell carcinoma, clear cell carcinoma, small cell carcinoma, neuroendocrine cell carcinoma, large cell carcinoma, and undifferentiated carcinoma). 30 birth year matched controls from the general Swedish population were matched to each case by applying incidence density sampling. Main outcome measures Conditional logistic regression was used to calculate odds ratios, interpreted as incidence rate ratios, for risk of ASC and RICC in relation to screening status and screening history, adjusted for education. Human papillomavirus distribution of ASC and RICC was based on available archival tumour tissues from most Swedish pathology biobanks. Results Women with two screening tests in the previous two recommended screening intervals had a lower risk of ASC (incidence rate ratio 0.22, 95% confidence interval 0.14 to 0.34) and RICC (0.34, 0.21 to 0.55), compared with women without any test. High risk human papillomavirus was detected in 148/211 (70%) cases with valid human papillomavirus results from tumour tissues. The risk reduction among women with tumours that were positive (incidence rate ratio 0.28, 0.18 to 0.46) and negative (0.27, 0.13 to 0.59) for high risk human papillomavirus was similar, compared with women who did not attend any test. Conclusions Cervical screening is associated with reduced risk of ASC and RICC, and most ASC and RICC are positive for high risk human papillomavirus. This evidence provides a benchmark for evaluating future cervical screening strategies.

[1]  M. Neovius,et al.  The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research , 2019, European Journal of Epidemiology.

[2]  P. Sparén,et al.  High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study , 2018, PLoS medicine.

[3]  M. Schiffman,et al.  Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening , 2018, Journal of the National Cancer Institute.

[4]  P. Sparén,et al.  Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer , 2018, British Journal of Cancer.

[5]  P. Ström,et al.  Effectiveness of cervical screening after age 60 years according to screening history: Nationwide cohort study in Sweden , 2017, PLoS medicine.

[6]  J. Dillner,et al.  Validation of a standardized extraction method for formalin-fixed paraffin-embedded tissue samples. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[7]  P. Sasieni,et al.  Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix? , 2016, International journal of cancer.

[8]  P. Ström,et al.  Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study , 2016, British Medical Journal.

[9]  Maria Hortlund,et al.  Laboratory audit as part of the quality assessment of a primary HPV-screening program. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[10]  K. Michaëlsson,et al.  Registers of the Swedish total population and their use in medical research , 2016, European Journal of Epidemiology.

[11]  E. Pirog,et al.  Human papillomavirus prevalence and type‐distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study , 2015, International journal of cancer.

[12]  S. Franceschi,et al.  European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination , 2015, Papillomavirus Research.

[13]  Jae-Weon Kim,et al.  Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix , 2014, International Journal of Gynecologic Cancer.

[14]  P. Sparén,et al.  Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality , 2014, BMJ : British Medical Journal.

[15]  Joakim Dillner,et al.  Screening and cervical cancer cure: population based cohort study , 2012, BMJ : British Medical Journal.

[16]  J. Ludvigsson,et al.  External review and validation of the Swedish national inpatient register , 2011, BMC public health.

[17]  N. Muñoz,et al.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.

[18]  J. Cuzick,et al.  Screening and adenocarcinoma of the cervix , 2009, International journal of cancer.

[19]  J. Cuzick,et al.  Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data , 2009, British medical journal.

[20]  J. Ludvigsson,et al.  The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research , 2009, European Journal of Epidemiology.

[21]  S. Pecorelli Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium , 2009 .

[22]  J. Carlson,et al.  Modified General Primer PCR System for Sensitive Detection of Multiple Types of Oncogenic Human Papillomavirus , 2009, Journal of Clinical Microbiology.

[23]  P. Sparén,et al.  Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. , 2008, Journal of the National Cancer Institute.

[24]  J. Dillner,et al.  Cervical cancer screening in Sweden. , 2000, European journal of cancer.

[25]  A. Mielck,et al.  Educational differences in smoking: international comparison , 2000, BMJ : British Medical Journal.

[26]  N. Pearce,et al.  What does the odds ratio estimate in a case-control study? , 1993, International journal of epidemiology.

[27]  R. Kurman,et al.  WHO classification of tumours of female reproductive organs , 2014 .

[28]  S. Franceschi,et al.  Human papillomavirus types in glandular lesions of the cervix: A meta‐analysis of published studies , 2013, International journal of cancer.

[29]  J. Vandenbroucke,et al.  Practice of Epidemiology What Do Case-Control Studies Estimate? Survey of Methods and Assumptions in Published Case-Control Research , 2008 .

[30]  Claus Rydahl Torp,et al.  [Where is the National Board of Health and Welfare?]. , 2003, Ugeskrift for laeger.

[31]  D. Peddie,et al.  Cervical screening. , 1999, The New Zealand medical journal.